Qilu pharmaceutical Shenjie leads the innovation of nerve repair drugs

Central nervous system injury is a common disease leading to human death and the main cause of human disability Every year, millions of new patients with central injury need to be treated in China, and the high mortality and disability rate of central injury patients, resulting in a huge social and economic burden on the country, families and patients As a result of the secondary injury of nerve cells, such as large amount of calcium influx, excitatory amino acid toxicity and oxidative free radicals, the neuron apoptosis was caused, and the recovery of nerve function was poor In the 1960s and 1970s, GM1 (monosialotetrahexosylganglioside) was found by klenk in Germany This substance is widely found in mammalian cell membranes, especially in the nervous system It is embedded in the double lipid membrane structure of cells, and is one of the important components of nerve cells, accounting for about 10% of the total lipid It occurs, grows, and plays an important role in the development of human nervous system It plays an essential role in the process of differentiation and regeneration, and is one of the main substances involved in the repair of neuropathy It has the magical effect of promoting neural remodeling, breaking the "non renewable" theory that has fettered human for more than 100 years In the 1980s and 1990s, GM1 preparation has been listed in Italy, Germany, Brazil, Argentina and other countries, bringing the dawn of treatment to countless patients with central nervous system injury In the 1990s, GM1 preparations were imported into China and rapidly used in clinical practice, which was widely recognized by experts However, the high price has deterred many patients and missed the opportunity of treatment It's broad-minded, but it's thick, but it's thin With strong R & D strength, Qilu pharmaceutical R & D personnel, after 8 years of painstaking independent R & D, first listed GM1 preparation in China in November 2004 - Shenjie, filling the market gap of domestic GM1, which is a breakthrough in foreign monopoly in the field of ganglioside products, and also brings good news to the vast number of patients with nerve injury Up to now, more than one million patients have gained clinical benefits and won the full trust of clinicians Qilu pharmaceutical also successfully obtained the new drug certificate and production approval of GM1 freeze-dried powder injection, so that Shenjie can serve patients with more dosage forms and specifications In 2007, in order to further accelerate the development of high-tech industry and promote the optimization and upgrading of industrial structure, the project of "development and industrialization of monosialotetrahexosylganglioside raw materials and injection" was awarded as "national high tech industrialization demonstration project" by the national development and Reform Commission The demonstration project is based on the national high-tech industry development project plan formulated by the CPC Central Committee and the State Council on strengthening technological innovation, developing high technology and realizing industrialization Only high-tech products with domestic and foreign leading level and independent intellectual property rights can stand out and promote me as a large-scale industry with international competitiveness The development of high-tech industry in China In January 2010, the 2009 National Science and technology award conference was held in the Great Hall of the people in Beijing 44 achievements in the field of medicine and health were awarded, among which Qilu pharmaceutical "research and industrialization of monosialotetrahexosylganglioside raw materials and injections" won the second prize of national science and technology progress award For a long time, the national science and technology progress award has been awarded to Chinese citizens and organizations who have made creative contributions in the process of technological research, technological development, technological innovation, promotion and application of advanced scientific and technological achievements, promotion of high-tech industrialization, and completion of major scientific and technological projects and plans The award is the highest honor of China's pharmaceutical industry technology innovation system Qilu pharmaceutical has become the first award-winning enterprise in the field of nerve repair medicine in China's pharmaceutical industry In November 2013, thanks to sufficient investment in science and technology, high-quality research team and continuous project approval of new products, CFDA and Qilu Pharmaceutical Co., Ltd reached an agreement to purchase the raw materials of monosialotetrahexosylganglioside sodium standard in large quantities, which not only proved that the quality of Shenjie produced by Qilu pharmaceutical was the highest in China, but also took the lead in the industry It has broken the industrial barriers of monopoly of imported drugs, and also marked that Qilu pharmaceutical's technological innovation and product quality have leaped to the highest level in China's pharmaceutical industry It is precisely because of the "harsh" requirements for the quality of products that Shenjie achieves and surpasses the quality and efficacy of imported similar drugs that doctors and patients benefit from The test results of the analysis and test center of China Pharmaceutical University show that the purity of Shenjie is 99.44%, which is nearly 9% higher than that of the imported GM1 by 90.41%, and the incidence of side effects is far lower than that of the same kind of imported products The qualified rate of market sampling has been kept at 100% for 10 consecutive years, which has built a solid foundation for large-scale clinical application Foundation In 2009, more than 20 authoritative neurologists in China, including Zhou Dingbiao, Professor of Neurosurgery, 301 Hospital of the PLA General Hospital, Jiang Jiyao, Professor of Renji Hospital Affiliated to Shanghai Jiaotong University Medical College, worked out the expert consensus on GM1 injection for the treatment of patients with brain and spinal cord injury (hereinafter referred to as the consensus) through multiple rounds of research, communication and consensus, GM1 is mainly used in the treatment of acute brain and spinal cord injury, and it is also used in the central nervous system injury caused by other reasons, including brain stroke, hypoxic-ischemic encephalopathy, cerebrospinal chiropractic and cerebrospinal radiation The release of the consensus is further The therapeutic significance of Shenjie in nervous system injury was confirmed In recent years, Shenjie has been listed as the recommended drug by authoritative literatures such as the guide to clinical treatment of craniocerebral trauma and the interpretation of clinical pathway treatment drugs, which further established the core position of the drug in the field of neuropathy repair Good efficacy and safety have not only been widely recognized by clinical experts, but also by the common people In December 2012, under the guidance of the drug administration department of the national health and Family Planning Commission and sponsored by the health newspaper, the eighth survey and selection activity of "safe drug use for the common people" with the theme of "setting an industry model to ensure drug safety" was officially launched The selection was conducted in the form of a questionnaire survey Among the results of the survey on safe drug use of the people in 31 provinces, autonomous regions and municipalities directly under the central government, the enterprises and products with the most use and voting by the people were selected "The gold cup and silver cup are not as popular as the common people." In this selection, Shenjie won the people's "reassuring medicine" award Ten years of market cultivation, Qilu pharmaceutical is building a dream future through deep and sophisticated technological innovation